TipRanks
Go Ultimate55% OFF

Seres Therapeutics (MCRB) Stock Forecast & Price Target

See the Price Targets and Ratings of:All AnalystsTop AnalystsPremium

MCRB Analyst Ratings

Moderate Buy
2Ratings
2Buy0Hold0Sell
Based on 2 analysts giving stock ratings to Seres Therapeutics in the past 3 months

MCRB Stock 12 Month Forecast

CHF 14.10▲(0.00% Upside)
Based on 2 Wall Street analysts offering 12 month price targets for Seres Therapeutics in the last 3 months. The average price target is CHF 14.10 with a high forecast of CHF 18.25 and a low forecast of CHF 9.96. The average price target represents a ― change from the last price of ―.
Highest Price TargetCHF 18.25Average Price TargetCHF 14.10Lowest Price TargetCHF 9.96

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for CH:MCRB
Price TargetFollowArticle
Canaccord GenuityCHF 18.25buy―Reiterated08/06/26
H.C. WainwrightCHF 9.96buy―Reiterated08/05/26
Piper SandlerCHF 16.59hold―Reiterated02/13/26
TD Cowen―buy―Reiterated11/05/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AORTArtivion
MDWDMediwound
IMUXImmunic
RZLTRezolute
DFTXDefinium Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Seres Therapeutics

3 Months
Joseph Thome
Joseph ThomeTD Cowen
Success Rate5/10 ratings generated profit
50%
Average Return
+1.80%

Copying Joseph Thome's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +1.80% per trade.

1 Year
John Newman
John NewmanCanaccord Genuity
Success Rate6/33 ratings generated profit
18%
Average Return
-13.34%

Copying John Newman's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -13.34% per trade.

2 Years
John Newman
John NewmanCanaccord Genuity
Success Rate1/33 ratings generated profit
3%
Average Return
-64.82%

Copying John Newman's trades and holding each position for 2 Years would result in 3.03% of your transactions generating a profit, with an average return of -64.82% per trade.

MCRB Analyst Recommendation Trends

02468Oct 25Nov 25Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26
Monthly rating counts for MCRB
RatingMay 26Jun 26Jul 26Aug 26Sep 26
Strong Buy24542
Buy00000
Hold00000
Sell00000
Strong Sell00000
total24542

In the current month, MCRB has received 2 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MCRB average Analyst price target in the past 3 months is 14.10.

MCRB Financial Forecast

CHF -3CHF -2CHF -1CHF 0CHF 1Q4 2025Q2 2026Q3 2026
HighCHF -0.55
ConsensusCHF -0.83
LowCHF -1.10

MCRB Earnings Forecast

Next quarter’s earnings estimate for MCRB is -CHF 0.83 with a range of -CHF 1.10 to -CHF 0.55. The previous quarter’s EPS was CHF 0.39. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.

CHF 164,767CHF 2.7MCHF 5.2MCHF 7.8MCHF 10.3MQ4 2025Q2 2026Q3 2026
HighCHF 10.3M
ConsensusCHF 5.23M
LowCHF 165K

MCRB Sales Forecast

Next quarter’s sales forecast for MCRB is CHF 5.23M with a range of CHF 164.77K to CHF 10.30M. The previous quarter’s sales results were CHF 606.35K. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

MCRB Stock Forecast FAQ

What is CH:MCRB’s average 12-month price target, according to analysts?
Based on analyst ratings, Seres Therapeutics’s 12-month average price target is CHF14.10.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Seres Therapeutics a Buy, Sell or Hold?
Seres Therapeutics has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
What is Seres Therapeutics’s share price target?
The average share price target for Seres Therapeutics is CHF14.10. This is based on 2 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is CHF18.25, and the lowest forecast is CHF9.96. The average share price target represents a 0.00% increase from the current price of ―.
What do analysts say about Seres Therapeutics?
Seres Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Street analysts.
How can I buy shares of Seres Therapeutics?
To buy shares of CH:MCRB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.